Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

RVNC Revance Therapeutics

27.000
+1.330+5.18%
Close 09/30 16:00 ET
26.990
-0.010-0.04%
Post Mkt Price 09/30 19:04 ET
High
27.320
Open
25.680
Turnover
72.41M
Low
25.460
Pre Close
25.670
Volume
2.71M
Market Cap
2.19B
P/E(TTM)
Loss
52wk High
29.510
Shares
81.12M
P/E(Static)
Loss
52wk Low
11.270
Float Cap
1.99B
Bid/Ask %
33.33%
Historical High
42.410
Shs Float
73.80M
Volume Ratio
1.88
Historical Low
9.880
Dividend TTM
--
Div Yield TTM
--
P/B
-843.75
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
3.67%
Amplitude
7.25%
Avg Price
26.756
Lot Size
1
Float Cap
1.99B
Bid/Ask %
33.33%
Historical High
42.410
Shs Float
73.80M
Volume Ratio
1.88
Historical Low
9.880
Dividend TTM
--
P/B
-843.75
Dividend LFY
--
Turnover Ratio
3.67%
Amplitude
7.25%
Avg Price
26.756
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
CEO: Mr. Mark J. Foley
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...